Compare KN & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KN | ZYME |
|---|---|---|
| Founded | 1946 | 2003 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Appliances | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.8B |
| IPO Year | 2013 | 2022 |
| Metric | KN | ZYME |
|---|---|---|
| Price | $24.95 | $23.23 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 11 |
| Target Price | $22.33 | ★ $38.90 |
| AVG Volume (30 Days) | 553.8K | ★ 625.3K |
| Earning Date | 05-08-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.94 | 33.33 |
| EPS | ★ 0.50 | N/A |
| Revenue | ★ $593,200,000.00 | $105,965,000.00 |
| Revenue This Year | $9.40 | $162.82 |
| Revenue Next Year | $6.98 | N/A |
| P/E Ratio | $50.84 | ★ N/A |
| Revenue Growth | 7.17 | ★ 38.87 |
| 52 Week Low | $12.19 | $9.03 |
| 52 Week High | $28.74 | $28.49 |
| Indicator | KN | ZYME |
|---|---|---|
| Relative Strength Index (RSI) | 42.02 | 46.30 |
| Support Level | $23.81 | $22.23 |
| Resistance Level | $25.33 | $23.66 |
| Average True Range (ATR) | 0.89 | 1.37 |
| MACD | -0.38 | 0.07 |
| Stochastic Oscillator | 23.93 | 17.07 |
Knowles Corp is engaged in the manufacturing of micro-acoustic microphones and balanced armature speakers, audio solutions, high-performance capacitors, and radio frequency filtering products. It operates in two segments; the Precision Devices segment specializes in the design and delivery of high-performance capacitor products and RF solutions; and Medtech & Specialty Audio segment designs and manufactures microphones and balanced armature speakers used in applications. The majority of its revenue comes from the Precision Devices. Geographically, it operates in United States, Asia, Other Americas, Europe and Others, out of which United States generates maximum revenue.
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The company is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.